Compare Illumina, Inc. (ILMN) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| ILMN | MDLZ | |
|---|---|---|
Market Cap | $39.95B | $77.43B |
Volume | 3,169,503 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $293.69 | $64.99 |
52-Week Low | $91.00 | $51.51 |
Typical Hold Time | 83 Days | 107 Days |
Enterprise Value | $41.31B | $97.78B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $0.73 exceeding expectations. Recent dividend increase to $0.52 per share and positive cash flow trends support the investment case. Valuation metrics include P/E of 22.22 and P/S of 1.97, while revenue growth continues with 2025 revenue reaching $38.54 billion.
MDLZ presents a compelling opportunity with 76% analyst buy ratings and $70.29 consensus price target representing 16% upside. The company demonstrates pricing power and emerging market momentum, though cocoa cost pressures and margin compression from 13.76% in 2023 to 6.36% in 2025 remain key watchpoints. Strong brand portfolio and defensive characteristics provide stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
